

- (21) Application No. 1922/73 (22) Filed 15 Jan. 1973
 (31) Convention Application No. 48 280 (32) Filed 11 Feb. 1972 in
 (33) Italy (IT)
 (44) Complete Specification published 18 April 1974
 (51) International Classification A61K 27/00//C07G 7/026
 (52) Index at acceptance
 A5B 20X 20Y 280 281 28Y 31X 31Y 382 38Y 39X 778
 C3H 2



(54) TREATMENT OF HEART DISEASES

(71) We, ISTITUTO FARMACOLOGICO SERONO, S.p.A. an Italian Body Corporate, of Via Casilina, 125, Rome, Italy, do hereby declare the invention for which we

5 pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—
 This invention relates to medicaments
 10 and, more particularly, to the therapeutical use in a pharmaceutical preparation of a phosphoprotein existing in nature which is called "Phosvitin". In 1885 Bunge (Z. Physiol. Chem. 9,49:1885) isolated from
 15 egg yolk an iron-containing phosphoprotein complex. A few years after, Huguenenq and Morel (Compt. Rend. 140, 1065; 1905) expressed the hypothesis that such a complex—which was named by them "haemotogen"—would be involved in the formation
 20 of the fowl embryo haemoglobin. This substance awakened the interest of many scientists; only, however, in 1949 were Mecham and Olcott (J.Am. Chem.Soc. 71, 3670; 1949) able to isolate from egg yolk a homogenous phosphoprotein fraction that was named by them "Phosvitin". The identity of the former "haemotogen" with such an "iron-phosvitin" complex was demon-
 30 strated in 1964 by O. Greengard et al. (Biochim. Biophys. Acta 90, 406, 1964).

The presence of phosvitin having been demonstrated in hen's eggs, an obvious consequence was that it was sought for in
 35 the eggs of other animals. Wallace et al. (Canad. J. Biochem. 44, 1647; 1966) isolated it from the eggs of vertebrata (tortoise, frog and so on); G. Schmidt et al. (Biochem. Biophys. Research Communications 18, 60, 40 1965) from the eggs of salmon; and Y. Macco et al. (J. Biol. Chem. 241, 3822; 1966) from the eggs of certain species of fish.

Further and deeper investigation was
 45 devoted to searching for phosvitin in the
 [Price 25p]

blood of hens and other animals since it was logical to suppose that its synthesis would occur in some organ and that phosvitin would be transferred from this organ to the egg yolk through the flow of blood. 50
 Thus, Mock et al. (Canad. J. Biochem. Physiol. 39,109; 1961) extracted phosvitin from the blood of non-laying hens to which estrogens had been administered, whereas Heald et al. (Biochem. J. 87, 571; 55 1963) demonstrated that a substance identical to the phosvitin existing in the egg yolk can be found in the blood of laying hens, even if the latter have not been treated with estrogens. Further studies 60 showed that phosvitin is synthesized in the liver and that its formation is hormone-controlled, being stimulated by the presence of estrogens.

From the chemical point of view, phosvitin is a phosphoprotein, that is, a protein containing removable phosphate groups which can be easily removed by treatment with alkali and enzymes (phosphokinases).

In its molecule 17 amino acids have been identified, 50% of this amino acid content being serine; hexoses (about 2.5%) and glucosamine (1.4%) are also present. The estimated molecular weight of phosvitin is 40,000 to 50,000 (Allerton et al., J. Biol. 75 Chem. 240,3892; 1965).

All percentages quoted in this specification are percentages by weight.

In the lyophilized state phosvitin appears as an off-white, odourless powder which is 80 soluble in water, 0.9% saline and 10% MgSO₄ solution, whereas it is insoluble in a solution containing less than 2.5% MgSO₄, and in the usual organic solvents. Its isoelectric point is at pH 1.8. 85

Phosvitin contains $9.6 \pm 0.3\%$ phosphorus, $11.6 \pm 0.4\%$ nitrogen and 0.3 to 0.4% iron. Molar ratio P/N = 2.5 to 2.9; ashes = $31 \pm 2\%$.

A solution containing 0.16% phosvitin 90

in 0.1 M potassium chloride at pH 6.5 to 6.7 has no significant absorption peak between $\lambda = 250$ and $\lambda = 290$ millimicrons. Paper electrophoresis (Whatman —registered Trade Mark—3 MM strips; 3 × 27 cm; 200 v-10 mA) of 0.3% phosvitin in borate buffer only shows a spot using the reagent specific to phosphate esters (blue spot), whereas Schwarz starch (a reagent specific to proteins) does not show any further spots. A further characteristic feature is that when treated with 1% toluidine blue in 7% acetic acid the paper strip shows a blue coloured spot which does not disappear when dipped in 7% acetic acid in methanol solution.

By following the usual procedure of polyacrylamide gel electrophoresis phosvitin gives one or more blue bands (which are due to the formation of molecular aggregations) when treated with 1% toluidine blue in 7% acetic acid.

By column chromatography on DEAE-cellulose phosvitin is eluted as a single homogenous fraction.

From the above information it can be clearly seen that phosvitin is a known substance which has been extensively studied by a number of investigators. No pharmacological-therapeutical actions of this substance have, however, been disclosed to date.

Surprisingly, investigations we have carried out have shown that phosvitin may be used as a medicament particularly suitable for use in curing and/or preventing such diseases as myocardial (in particular dysmetabolic myocardial) diseases and coronary heart diseases, as well as for use as an adjuvant in cases of heart failure.

Accordingly the present invention provides a pharmaceutical preparation comprising phosvitin together with a pharmaceutically acceptable carrier or diluent. Preferably, the weight ratio phosvitin: carrier or diluent is from 1:1 to 1:0.1. In one embodiment the preparation is in lyophilized form and phosvitin is utilized with glyccoll, the weight ratio phosvitin: glyccoll preferably being about 1:0.5.

An especially preferred embodiment of this invention is a pharmaceutical preparation suitable for daily injection in human beings which comprises from 0.1 to 1 g. phosvitin as a daily dose.

The present invention also provides a process for preparing a pharmaceutical preparation for use in the treatment of heart diseases, which process comprises dissolving phosvitin and a pharmaceutically acceptable carrier or diluent in apyrogenic distilled water, filtering the solution through a sterilizing filter and lyophilizing the filtrate to obtain a pharmaceutical preparation which is suitable for injection.

Preferably, in such a process the pharmaceutically acceptable carrier or diluent is glyccoll.

The acute toxicity of the medicament of this invention was determined in mice intravenously, intraperitoneally and orally. The tests carried out on adult male Swiss mice having the average weight of 18 g. gave the following results:

LD₅₀ = 334.41 mg/kg i.v.

LD₅₀ = 4050 mg/kg i.p.

LD₅₀ > 8000 mg/kg orally

The following specific Examples are now given to further illustrate the invention.

Examples 1 and 2 merely illustrate the pharmacological properties of phosvitin and do not describe preparations in accordance with the invention.

EXAMPLE 1

Male albino Wistar rats having the average weight of 240 g. were first anaesthetized with 35 mg/kg i.p. sodium pentobarbital (Nembutal) and then treated with 2 I.U./kg vasopressin (Pitressin) by quick intravenous infusion, then given phosvitin in doses of 1000 mg/kg i.p. or 750 mg/kg i.p. plus 250 mg/kg i.v.

In both cases a marked reduction or prevention of the main electrocardiographic changes induced by the intravenous administration of vasopressin was observed.

EXAMPLE 2

Male albino Wistar rats having the average weight of 240 g. were first brought into a state of hypoxia by forced ventilation of an air/nitrogen mixture (30:70 by volume) and treated with 2-3 mcg./kg i.v. nor-adrenaline, then given phosvitin in a dose of 1000 mg/kg i.p.

A marked reduction or prevention of the main electrocardiographic changes induced by the intravenous administration of nor-adrenaline to animals brought into a state of hypoxia was observed.

EXAMPLE 3

An isolated guinea-pig atrium dipped in Ringer-Krebs-Henselait solution was made hypodynamic by submitting it to prolonged electrical stimulation at the constant frequency of 2 stimuli per second (5 milliseconds per stimulus).

The increase in contraction amplitude induced by the addition of 1 mcg. per ml. of bath contents of either nor-adrenaline or adrenaline was markedly enhanced in both cases by the addition of phosvitin in a dose of 25 mcg/ml of bath contents.

Further experiments showed that the medicament of the invention lacks any coronarodilator activity.

From the above it clearly appears that phosvitin is a highly useful therapeutical tool in myocardial (in particular dysmetabolic myocardial) diseases, in coronary heart diseases, and as an adjuvant in cases

of heart failure.

A typical preparation of phosvitin prepared by extraction from hen's egg yolk is made as follows:—

- 5 Several eggs were broken, the yolk being separated from the albumen and extracted several times with ethanol. The alcoholic phospholipid-containing liquor was put aside whereas the protein residue was
- 10 squeezed and extracted several times with acetone. The acetonetic neutral fat (egg oil) —containing liquor was put aside whereas the protein residue, deprived both of phospholipids and lipids, was extracted with
- 15 10% aqueous magnesium sulfate solution. Raw phosvitin was precipitated by diluting the saline solution with 3.4 volumes of water and the precipitate dissolved in 10% sodium chloride aqueous solution. Further
- 20 magnesium sulfate was added up to 10% concentration, the saline was then filtered and phosvitin was precipitated again by diluting the filtrate with 3.4 volumes of water. The thus-obtained phosvitin precipitate was first dissolved in 10% NaCl, the
- 25 saline desalinated by means of dialysis, filtered and lyophilized.

- Lyophilized phosvitin may be mixed with suitable carriers or diluents such as
- 30 mannose, lactose and glyccoll in a weight ratio phosvitin: carrier or diluent generally ranging from 1:1 to 1:0.1. In accordance with the invention it has been found that, among suitable carriers or diluents, gly-
 - 35 cocoll particularly helps solution of the lyophilized product in water or saline. The preferred phosvitin: glyccoll ratio is about 1:0.5. A preferred aspect of the present invention is a pharmaceutical preparation
 - 40 in lyophilized form containing phosvitin and glyccoll in a weight ratio of about 1:0.5. The present pharmaceutical preparations may also contain a common antiseptic agent, e.g. sodium thimerosal
 - 45 (Merthiolate).

- The following is a typical example of a method which may be used for preparing ampoules or vials containing a pharmaceutical preparation in accordance with the
- 50 invention and in lyophilized form.

EXAMPLE 4

- An aqueous solution was prepared having the following composition:
- | | | |
|----|----------------------------------|---------|
| | Phosvitin | 10 g. |
| 55 | Glyccoll | 5 g. |
| | Sodium Merthiolate | 10 mg. |
| | Apyrogenic distilled water up to | 100 ml. |
- The first three ingredients were dissolved in the water at room temperature (22 to
- 60 25°C) with stirring. The resulting solution was filtered through a sterilizing SEITZ EK filter and put into 3 ml. dark-glass ampoules or vials in an amount of 1 ml. per ampoule or vial. Freezing and
 - 65 lyophilization were carried out subse-

quently. Thus, each ampoule or vial of lyophilized product contained 100 mg. phosvitin and 50 mg. glyccoll.

A pharmaceutically effective daily dose in man has been found to be in the range of from 0.1 to 1 g. phosvitin. A preferred way of administration is by intramuscular or intravenous injection.

The invention includes a method for the treatment of heart disorders in a non-human animal such as myocardial diseases, coronary heart diseases, and heart failure, which method comprises administering to the non-human animal a pharmaceutically effective amount of phosvitin.

It should be clearly understood that we make no claim herein to solutions or suspensions of phosvitin in common solvents.

Subject to the foregoing disclaimer,

WHAT WE CLAIM IS:—

1. A pharmaceutical preparation comprising phosvitin together with a pharmaceutically acceptable carrier or diluent.

2. A pharmaceutical preparation as claimed in claim 1, wherein the weight ratio phosvitin: carrier or diluent is from 1:1 to 1:0.1.

3. A pharmaceutical preparation as claimed in claim 1 or claim 2, which preparation is in lyophilized form and comprises phosvitin and glyccoll.

4. A pharmaceutical preparation as claimed in claim 3, in which the weight ratio phosvitin: glyccoll is about 1:0.5.

5. A pharmaceutical preparation as claimed in any one of the preceding claims additionally containing an antiseptic agent.

6. A pharmaceutical preparation as claimed in claim 5, wherein the antiseptic agent is sodium thimerosal.

7. A pharmaceutical preparation as claimed in any one of the preceding claims, which preparation is suitable for daily injection in human beings and comprises from 0.1 to 1 g. phosvitin as a daily dose.

8. A process for preparing a pharmaceutical preparation for use in the treatment of heart diseases, which process comprises dissolving phosvitin and a pharmaceutically acceptable carrier or diluent in apyrogenic distilled water, filtering the solution through a sterilizing filter and lyophilizing the filtrate to obtain a pharmaceutical preparation which is suitable for injection.

9. A process as claimed in claim 8, wherein the pharmaceutically acceptable carrier or diluent is glyccoll.

10. A process as claimed in claim 9, substantially as hereinbefore described in Example 4.

11. A pharmaceutical preparation whenever prepared in a process as claimed in any one of claims 8 to 10.

12. A process as claimed in claim 8, wherein the phosvitin component of the preparation is prepared by a process substantially as hereinbefore described in 5 Example 3.

13. A pharmaceutical preparation as claimed in claim 1, whenever prepared in a process as claimed in claim 12.

14. A pharmaceutical preparation as 10 claimed in claim 1 substantially as hereinbefore described in Example 3 or Example 4.

15. A method for the treatment of heart disorders in a non-human animal such as

myocardial diseases, coronary heart diseases, 15 and heart failure, which method comprises administering to the non-human animal a pharmaceutically effective amount of phosvitin.

16. A method as claimed in claim 5, 20 wherein the phosvitin is administered in the form of a pharmaceutical preparation as claimed in any one of claims 1 to 7, 11, 13 or 14.

BOULT, WADE & TENNANT

Chartered Patent Agents

34 Cursitor Street, London EC4A 1PQ

Printed for Her Majesty's Stationery Office by The Tweeddale Press Ltd., Berwick-upon-Tweed, 1974.
Published at the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.